1 / 6

ABRF 2005 Microarray Roundtable

ABRF 2005 Microarray Roundtable. Microarray Platform Comparability: Importance of Informatics & Design Facilitator: Dr. Andrew I. Brooks University of Rochester Medical Center University of Medicine & Dentistry of New Jersey / Rutgers University. Academic Anna Rogojina, Ph.D. St. Judes

vartan
Download Presentation

ABRF 2005 Microarray Roundtable

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ABRF 2005 Microarray Roundtable Microarray Platform Comparability: Importance of Informatics & Design Facilitator: Dr. Andrew I. Brooks University of Rochester Medical Center University of Medicine & Dentistry of New Jersey / Rutgers University

  2. Academic Anna Rogojina, Ph.D. St. Judes Mark Parrish, Ph.D. Rosetta Inpharmatics Shawn Levy, Ph.D. Vanderbilt Margaret Cam, Ph.D. NIDDK, NIH Industrial Peter Webb, Ph.D. Agilent Technologies Steven Smith Nimblegen Systems Timothy Sendera, Ph.D. GE Healthcare Stephen Lincoln Affymetrix John Burrill, Ph.D. Applied Biosystems Roundtable Panelist

  3. Roundtable Rules • A series of pre-decided questions will be asked by our Academic panelists. • All Industrial panelists will be given an opportunity to answer. • Questions will be taken by the audience a the end of the program (please state your name and institution). • NO marketing, product promotion or derogatory targeted questions or comments will be allowed by the facilitator. *Biographies, Panel Questions and Literature pertaining to roundtable objectives is available in the back of the room and will be posted to the MARG website *Transcripts from the roundtable will be made available on the MARG website

  4. Technology Overview I • GE Healthcare • Genetic content from public domain • 30mer oligonucleotides (spotted) • In “most” cases one probe per gene • Fluorescent detection • One Color • Affymetrix • Genetic content from public domain • 25mer oligonucelotides (in situ synthesis) • Multiple probe sets per gene (3’UTR) • Fluorescent detection • One Color

  5. Technology Overview II • Agilent Technologies • Catalogue array content from public domain • 60mer oligonucleotides (in situ synthesis) • In “most” cases one probe per gene • Fluorescent detection • Two-Color • Nimblegen Systems • Catalogue array content from public domain • Variety of oligo lengths (24-85 bp) (in situ synthesis) • Number of probes selected by investigator • Fluorescent detection • One or Two Color

  6. Technology Overview III • Applied Biosystems • Genetic content from Celera Discovery System • 60mer oligonucleotides (spotted) • 85% single probe per gene • Chemiluminescence detection • One Color

More Related